Skip to main content
. 2014 Oct;88(20):11760–11773. doi: 10.1128/JVI.01631-14

FIG 7.

FIG 7

Identification of the core sequences and HLA restrictions of subdominant epitopes in donor 2. (A) (i) The 13-mer peptides within 18-mer M1(37-54) and M1(43-60) sequences were screened by ICS; the 18-mer results are shown by open bars. (ii) Several recognized 13-mers and the corresponding 18-mers were titrated. (iii to v) HLA restriction of the core 13-mer M143-55 was determined by HLA class II antibodies (iii) and partial HLA matching of BLCLs (iv and v). (B) (i) The 13-mer peptides within 18-mer M1(97-114) and M1(103-120) were screened; 18-mer results are shown by open bars. (ii to v) Three 13-mer overlapping peptides and two corresponding 18-mer peptides were titrated to compare their activities (ii), and HLA restriction of 13-mer M1101-113 was analyzed with HLA class II antibodies (iii) and partially HLA-matched BLCLs (iv and v). (C) (i) The 13-mer peptides within 18-mer NP109-126 and NP115-132 were screened as in panel A. (ii to iv) The 13-mer peptides NP114-126 and NP115-127 showed identical potentials when titrated, indicating that the core sequence is likely NP115-126 (ii), and HLA restriction of NP115-127 was determined by partial HLA matching of BLCLs (iii and iv).